The written work
Reports
Where a company has been researched in full rather than screened, the work is written up and published here. Every figure carries instructions for reproducing it, and every report is preceded by a letter to the parties named in it, inviting correction.
Series · Theriva Biologics, Inc.
Reports Nos. 1 to 3
Subject: Theriva Biologics, Inc. (NYSE American: TOVX), formerly Synthetic Biologics, Inc. SEC CIK 0000894158. This was the first company put through the questions, and the series is the worked example the method was built from. See the test results for TOVX →
Executive Summary — the Triggered Short™ model
Capital structure since 2025, the May 2025 financing, the October 2025 warrant inducement, and the hypothetical model, with all calculations marked illustrative. Published July 20, 2026.
Summary
Findings only, numbered, each pointing to the report that carries the support.
The record requests
The stockholder meeting of December 15, 2025; three consecutive meetings called without a quorum; sworn demands for inspection of corporate records; the company's rejection through outside counsel; certified mail documentation and return receipts.
The warrant cycle
Issue, decline, repricing, replacement warrants at 200 percent, exercise. Documented from company filings only. Includes a dated forward prediction.
The market record
FINRA reported short interest, FINRA average daily volume, price and volume history, and turnover against shares outstanding, set against the filing dates in 2B. Third-party data only.
Professional recurrence — Exhibit J
Counsel, placement agent, and directors appearing across multiple issuers in the same financing structure. Counts drawn from EDGAR full-text search.
Correspondence
Requests for comment
Four letters were sent before publication, each setting out the specific statements of fact intended for print and inviting correction. Each letter states that any response will be published in full and unedited.
| Recipient | Attention | Delivered | Response due | Response |
|---|---|---|---|---|
| Theriva Biologics, Inc. | Chief Executive Officer; Corporate Secretary | Aug 12, 2026 | Aug 20, 2026 | — |
| A.G.P. / Alliance Global Partners | Chief Compliance Officer | Aug 12, 2026 | Aug 19, 2026 | — |
| Blank Rome LLP | Leslie Marlow | Aug 12, 2026 | Aug 19, 2026 | — |
| Empery Asset Management, LP | Managing Members | Aug 12, 2026 | Aug 19, 2026 | — |
Responses received will be posted here in full. Where no response is received, that will be stated.